A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)

Trial Profile

A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Vorinostat (Primary) ; Capecitabine
  • Indications Head and neck cancer; Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 13 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top